Policy | September 16, 2025
FDA launches crackdown on deceptive drug advertising
The FDA is beginning rulemaking to close the “adequate provision” loophole
The FDA is beginning rulemaking to close the “adequate provision” loophole
Experts urge early detection & better access to care
Studies suggest that the protein Sclerostin plays a key role in the dysregulation of bone metabolism
STABILIZE-CKD and DIALIZE-Outcomes trials are part of the CRYSTALIZE evidence programme
The drug will be marketed by Sun Pharma under the brand name RYTSTAT
The Phase IV DREAM-CKD trial will enrol 1004 CKD patients in India, including 502 dialysis dependent, 502 dialysis independent CKD patients with anemia.
AstraZeneca and Indian Society of Nephrology aim to help clinicians and healthcare practitioners to provide holistic kidney care to their patients.
The study, which enrolled 35 Japanese patients, evaluated the percent change from baseline in the 24-hour urine protein-to-creatinine ratio
Both companies will promote, market and distribute Sodium Zirconium Cyclosilicate in India under different brand names
The expanded approval allows Kerendia to be prescribed to heart failure patients with a LVEF of 40% or more
Subscribe To Our Newsletter & Stay Updated
